NCT06851676 (FOCUS) is a NA clinical trial of water supplemented by calcium in Osteopenia, Osteoporosis, sponsored by ANTIMO.

Who is sponsoring NCT06851676?

NCT06851676 is sponsored by ANTIMO.

What drugs are being tested in NCT06851676?

Interventions in NCT06851676: water supplemented by calcium, Water (Placebo).

What condition does NCT06851676 study?

NCT06851676 studies Osteopenia, Osteoporosis, Sarcopenia.

Is NCT06851676 still recruiting?

NCT06851676 is currently recruiting now. Last updated 28 February 2025.

Last reviewed 2025-02-28 · How we verify

NCT06851676: FOCUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Functional and Metabolic Effects of Fonte Fausta® Water on Bone and Muscle Health in Osteoporotic Patients

Recruiting now NA Last updated 28 February 2025

What this trial tests

NA trial testing water supplemented by calcium in Osteopenia, Osteoporosis in 100 participants. Currently enrolling.

Timeline

10 July 2024

Primary endpoint
10 July 2025

10 September 2025

Quick facts

Lead sponsor	ANTIMO
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	10 July 2024
Primary completion	10 July 2025
Estimated completion	10 September 2025
Sites	1 location across Italy

Drugs / interventions tested

water supplemented by calcium
Water (Placebo) — full drug profile →

Conditions studied

Osteopenia, Osteoporosis — all drugs for Osteopenia, Osteoporosis →
Sarcopenia — all drugs for Sarcopenia →

Sponsor

ANTIMO

Who can join

65 and older, any sex, with Osteopenia, Osteoporosis or Sarcopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical study investigates the effects of Fonte Fausta® water on bone and muscle metabolism, as well as quality of life, in patients with osteoporosis or osteopenia, with or without sarcopenia. Conducted as a multicenter, triple-arm trial, it evaluates functional and biochemical markers over 12 months. Patients are randomized into groups receiving either Fonte Fausta® or standard mineral water, with assessments including laboratory tests, bioimpedance analysis, physical and nutritional evaluations, bone density measurements, and quality of life surveys.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of a Naturally Calcium and Magnesium-Rich Mineral Water on Musculoskeletal Fragility: A Randomized, Double-Blind Controlled Trial.
Moretti A, Liguori S, Paoletta M, Gimigliano F, et al · · 2026 · PMID 41683292 · DOI 10.3390/nu18030470

Verify or expand the search:

Other recruiting trials for Osteopenia, Osteoporosis

Currently open trials in the same condition.

NCT06018467 — Senolytics to Improve Osteoporosis Therapy · Phase 2 · active not recruiting
NCT06781541 — Physical Activity and Disability Prevention in Postmenopausal Women · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06851676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ANTIMO
Last refreshed: 28 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06851676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing